Bavarian Nordic vaccine filling facility approved by US and EU

Following an FDA inspection and an assessment by the EMA’s expert committee, the vaccine maker has been authorized to manufacture its monkeypox vaccine at its own fill and finish facility in Denmark.

Bavarian Nordic's Danish filling facility has been given the nod by EU and US officials to begin making monkeypox shots | Photo: Bavarian Nordic / PR

Danish vaccine maker Bavarian Nordic has been given the green light by EU and US regulatory authorities to begin the production of its monkeypox vaccine at its own fill and finish facility in Denmark, the firm reported in a press release on Wednesday.

This follows a site inspection by the US Food and Drug Administration (FDA) in the beginning of July and an application assessment by the European Medicines Agency’s (EMA) expert committee, the Committee for Medicinal Products for Human use (CHMP), in June.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs